Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation

Autonomix Medical, Inc., a medical device company specializing in precision nerve-targeted treatments, announced on May 19, 2026, that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 12,544,131. The patent, titled *Systems, Methods, and Devices for Monitoring and Treatment of Tissues Within And/Or Through a Lumen Wall*, strengthens the company’s intellectual property portfolio for its transvascular neuromodulation platform. The patent covers catheter-based systems designed to operate within bodily lumens, allowing deployable probes to penetrate and access tissues and nerves outside vessel walls. It includes claims for multi-site electrophysiological sensing—targeting primary, secondary, and reference sites—to improve signal quality and procedural confidence. Methods for assessing treatment completion via electrophysiological signal processing are also protected, enabling detection of changes in neural activity patterns. A key feature of the patent is closed-loop control, which adjusts stimulation or therapeutic energy delivery in real-time based on live electrophysiological feedback. This supports adaptive neuromodulation and more precise procedural workflows. The patent encompasses a broad range of electrophysiological signals and therapeutic modalities, with potential applications across multiple nerve-targeted indications. Autonomix Medical’s CEO, Brad Hauser, emphasized the patent’s significance in addressing a critical gap in current neuromodulation procedures: the lack of real-time confirmation that targeted nerves have been effectively treated. The technology enables objective validation of treatment efficacy and dynamic adjustments, aligning with the company’s mission to enhance procedural outcomes through next-generation tools. The newly granted patent expands Autonomix’s global intellectual property portfolio, which includes issued and pending applications for transvascular and neuromodulation technologies. These cover nerve mapping, signal processing, and controlled micro-ablation across multiple organ systems. The company’s IP strategy aims to provide broad protection for its innovative platforms in clinical applications. Autonomix Medical, Inc. is listed on NASDAQ under the ticker AMIX and remains focused on advancing precision nerve-targeted treatments through its proprietary transvascular systems.